Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Drugs & Aging

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40266-018-0556-0PMID 29971609
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cirrhotic patients and older people

  2019cited by this paper
• primary :

  2019cited by this paper
• Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second‐line Therapy for Patients With Autoimmune Hepatitis

  2017cited by this paper
• Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy

  2017cited by this paper
• Efficacy and Limitations of Budesonide as a Second‐Line Treatment for Patients With Autoimmune Hepatitis

  2017cited by this paper
• [Autoimmune hepatitis].

  2015cited by this paper
• Autoimmune hepatitis

  2015cited by this paper
• Autoimmune hepatitis--Update 2015.

  2015cited by this paper
• Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management.

  2015cited by this paper
• Liver transplantation and autoimmune hepatitis.

  2015cited by this paper
• Systematic review with meta‐analysis: clinical manifestations and management of autoimmune hepatitis in the elderly

  2014cited by this paper
• Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis

  2014cited by this paper
• Autoimmune hepatitis in southern Israel: A 15‐year multicenter study

  2013cited by this paper
• Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis

  2013cited by this paper
• Histological discrimination between autoimmune hepatitis and drug‐induced liver injury

  2012influential reference
• Liver transplantation in autoimmune liver diseases.

  2011cited by this paper
• AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE The Use of Liver Biopsy Evaluation in Discrimination of Idiopathic Autoimmune Hepatitis Versus Drug-Induced Liver Injury

  2011cited by this paper
• Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment.

  2011cited by this paper
• Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis.

  2011cited by this paper
• The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes

  2011cited by this paper
• Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria.

  2011cited by this paper
• Reversal of liver cirrhosis in autoimmune hepatitis.

  2011cited by this paper
• Drug-Induced Autoimmune-Like Hepatitis

  2011cited by this paper
• [The diagnosis and treatment of autoimmune hepatitis].

  2010cited by this paper
• Therapeutic Options to Treat Autoimmune Hepatitis in 2009

  2010cited by this paper
• Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials.

  2010cited by this paper
• Drug‐induced autoimmune hepatitis: Clinical characteristics and prognosis

  2010cited by this paper
• Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis.

  2010cited by this paper
• Infliximab-related hepatitis: discussion of a case and review of the literature

  2010cited by this paper
• Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis

  2010cited by this paper
• Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?

  2010cited by this paper
• Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.

  2010cited by this paper
• Review article: the modern management of autoimmune hepatitis

  2010cited by this paper
• Primary liver transplantation for autoimmune hepatitis: A comparative analysis of the European Liver Transplant Registry

  2010cited by this paper
• Diagnosis and management of autoimmune hepatitis

  2010cited by this paper
• Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy.

  2010cited by this paper
• Aetiopathogenesis of autoimmune hepatitis.

  2010cited by this paper
• Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men

  2010cited by this paper
• Risk factors for idiosyncratic drug-induced liver injury.

  2010cited by this paper
• Features and consequences of untreated type 1 autoimmune hepatitis

  2009cited by this paper
• Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients.

  2009cited by this paper
• The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice.

  2009cited by this paper
• Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis.

  2008cited by this paper
• Clinical Features, Differential Diagnosis and Treatment of Autoimmune Hepatitis in the Elderly

  2008cited by this paper
• Simplified criteria for the diagnosis of autoimmune hepatitis

  2008cited by this paper
• Frequency, Behavior, and Prognostic Implications of Antimitochondrial Antibodies in Type 1 Autoimmune Hepatitis

  2008cited by this paper
• Long‐term follow‐up of antimitochondrial antibody–positive autoimmune hepatitis

  2008cited by this paper
• Progress in the diagnosis and treatment of autoimmune hepatitis.

  2008cited by this paper
• Safety issues in the management of autoimmune hepatitis

  2008cited by this paper
• Liver involvement in celiac disease.

  2008cited by this paper
• Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study.

  2008cited by this paper
• Safety issues in the management of autoimmune hepatitis.

  2008cited by this paper
• Corticosteroid-Responsive Cryptogenic Chronic Hepatitis: Evidence for Seronegative Autoimmune Hepatitis

  2007cited by this paper
• Relapse Following Treatment Withdrawal in Patients with Autoimmune Chronic Active Hepatitis

  2007cited by this paper
• Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.

  2007cited by this paper
• Steroid treatment for severe acute cryptogenic hepatitis.

  2007cited by this paper
• The Canadian Celiac Health Survey

  2007cited by this paper
• Long‐term follow‐up of patients with mild to moderate drug‐induced liver injury

  2007cited by this paper
• Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly

  2006cited by this paper
• Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre.

  2006cited by this paper
• Budesonide induces complete remission in autoimmune hepatitis.

  2006cited by this paper
• Thiopurine Methyltransferase Deficiency and Azathioprine Intolerance in Autoimmune Hepatitis

  2006cited by this paper
• Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis

  2006cited by this paper
• Drug‐induced liver injury: Summary of a single topic clinical research conference

  2006cited by this paper
• High prevalence of celiac disease in autoimmune hepatitis detected by anti‐tissue tranglutaminase autoantibodies

  2005cited by this paper
• The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates

  2005cited by this paper
• Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome

  2005cited by this paper
• Budesonide in previously untreated autoimmune hepatitis

  2005cited by this paper
• Diverse manifestations and evolving treatments of autoimmune hepatitis.

  2005cited by this paper
• Transplant immunosuppressive agents in non‐transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus

  2005cited by this paper
• Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.

  2005cited by this paper
• Diverse manifestations and evolving treatments of autoimmune hepatitis.

  2005cited by this paper
• Diagnosis and treatment of autoimmune hepatitis at age 65 and older

  2005cited by this paper
• Anti‐tRNP(ser)sec/SLA/LP autoantibodies. Comparative study using in‐house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs

  2005cited by this paper
• Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.

  2004cited by this paper
• Drug-induced hepatitis, drug-induced autoimmunity or classical autoimmune hepatitis: how can we differentiate?

  2004influential reference
• Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis.

  2004cited by this paper
• Clinicopathological features of acute-onset autoimmune hepatitis.

  2003cited by this paper
• The components of excess mortality after hip fracture.

  2003cited by this paper
• Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC.

  2003cited by this paper
• Immune-mediated drug-induced liver disease.

  2002cited by this paper
• Treatment strategies in autoimmune hepatitis.

  2002cited by this paper
• Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics

  2002cited by this paper
• Diagnosis and treatment of autoimmune hepatitis

  2002cited by this paper
• Celiac disease in autoimmune cholestatic liver disorders

  2002cited by this paper
• Prognosis of Symptomatic Versus Asymptomatic Autoimmune Hepatitis: A Study of 68 Patients

  2002cited by this paper
• Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis

  2002cited by this paper
• Anti-Soluble Liver Antigen/Liver-Pancreas (SLA/LP) Antibodies in Pediatric Patients with Autoimmune Hepatitis

  2002cited by this paper
• Secondary causes of osteoporosis.

  2002cited by this paper
• AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASE. DIAGNOSIS AND TREATMENT OF AUTOIMMUNE HEPATITIS

  2002cited by this paper
• Autoimmune hepatitis in the elderly

  2001cited by this paper
• Anti-SLA antibody is a marker of severity of liver damage in patients with autoimmune liver disease

  2001cited by this paper
• Extracorporeal liver support with albumin dialysis (MARS)-clinical trial experience from 19 centers

  2001cited by this paper
• Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis.

  2000cited by this paper
• Re-analysis of clinical features of 89 patients with autoimmune hepatitis using the revised scoring system proposed by the International Autoimmune Hepatitis Group.

  2000cited by this paper
• High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis.

  2000cited by this paper
• Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system.

  2000cited by this paper
• Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis.

  2000cited by this paper
• Mortality after all major types of osteoporotic fracture in men and women: an observational study.

  1999cited by this paper
• International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

  1999cited by this paper

• Advances in the Treatment of Autoimmune Hepatitis

  2024cites this paper
• Autoimmune Hepatitis with Metabolic Dysfunction-associated Fatty Liver Disease

  2024cites this paper
• KASL clinical practice guidelines for management of autoimmune hepatitis 2022

  2023cites this paper
• The Translational Bridge between Inflammation and Hepatocarcinogenesis

  2022cites this paper
• The Aging Human Liver: The Weal and Woe of Evolutionary Legacy

  2022cites this paper
• The liver and gallbladder in the geriatric population

  2022cites this paper
• The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis

  2021cites this paper
• Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome

  2021cites this paper
• The aged liver: Beyond cellular senescence.

  2020cites this paper
• The Gastrointestinal Tract in the Elder

  2020cites this paper
• Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population

  2019cites this paper
• Expression and significance of Th17 cells and related factors in patients with autoimmune hepatitis.

  2019cites this paper
• Cirrhotic patients and older people

  2019cites this paper
• Treat autoimmune hepatitis in the elderly with corticosteroids + azathioprine to reduce the risk of corticosteroid-related toxicity

  2018influential citation
• Treat autoimmune hepatitis in the elderly with corticosteroids + azathioprine to reduce the risk of corticosteroid-related toxicity

  2018cites this paper
• Acute Liver Failure

  2018cites this paper